ROCKVILLE, Md., May 6, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

BofA Securities Health Care Conference 2025
Presentation: Tuesday, May 13, 2025 at 5:00 p.m. PT
Location: Las Vegas, NV

RBC Global Healthcare Conference
Fireside Chat: Tuesday, May 20, 2025 at 11:30 a.m. ET
Location: New York, NY

H.C. Wainwright BioConnect
Fireside Chat: Tuesday, May 20, 2025 at 4:00 p.m. ET
Location: New York, NY

Stifel Virtual Ophthalmology Forum 
Fireside Chat: Tuesday, May 27, 2025 at 9:30 a.m. ET
Location: Virtual

UBS Spring Biotech Conference
1x1 Investor Meetings: Tuesday, June 24, 2025
Location: New York, NY

Live webcasts of select presentations and fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.

REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack
Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investors:
George E. MacDougall
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.